PMID: 18413064Apr 17, 2008Paper

Nuclear reprogramming to produce cloned mice and embryonic stem cells from somatic cells

Reproductive Biomedicine Online
Sayaka WakayamaTeruhiko Wakayama

Abstract

Cloning methods in mice are now well described and are becoming routine. However, the frequency at which cloned mice are produced remains below 5%, irrespective of the nucleus donor species or cell type. Only a few laboratories have made clones from adult mouse somatic cells and most strains have never produced cloned mice. On the other hand, nuclear transfer can be used to generate human embryonic stem (ntES) cell lines from a patient's own somatic cells. It has been shown that such cells can be generated relatively easily from a variety of mouse genotypes and cell types of both sexes, even though it may be more difficult to generate clones directly. This technique could be used in regenerative medicine and, in theory, in infertility clinics to treat completely infertile individuals. However, these results suggest that the reprogramming integrity of each cloned embryo differs: some cloned embryos can be converted to ntES cells, but these embryos cannot achieve full term development. This review outlines the nature of genomic reprogramming potential and its application, and suggests new approaches to avoid the ethical problems of creating embryos by nuclear transfer.

References

Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·T WakayamaP Mombaerts
Feb 2, 2000·Nature Genetics·T WakayamaR Yanagimachi
Feb 2, 2000·Nature Genetics·W M RideoutR Jaenisch
Dec 6, 2000·Genesis : the Journal of Genetics and Development·E KawaseR A Pedersen
Mar 10, 2001·Molecular Reproduction and Development·T Wakayama, R Yanagimachi
Jan 12, 2002·Science·Kimiko InoueAtsuo Ogura
Feb 12, 2002·Nature Genetics·Narumi OgonukiAtsuo Ogura
Apr 12, 2003·Science·Calvin SimerlyGerald Schatten
Sep 11, 2004·Biochemical and Biophysical Research Communications·Sho SendaKunio Shiota
Jan 14, 2005·The Journal of Reproduction and Development·Sayaka WakayamaTeruhiko Wakayama
Apr 12, 2005·Reproductive Biomedicine Online·J B Gurdon
Jun 21, 2005·Current Biology : CB·Kimiko InoueAtsuo Ogura
Sep 20, 2005·Reproductive Biomedicine Online·Miodrag StojkovicAlison Murdoch
Jun 24, 2006·Reproductive Biomedicine Online·Philippe CollasJohn Arne Dahl
Nov 2, 2006·The Journal of Reproduction and Development·Satoshi KishigamiTeruhiko Wakayama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cell Fate Conversion By mRNA

mRNA-based technology is being studied as a potential technology that could be used to reprogram cell fate. This technique provides the potential to generate safe reprogrammed cells that can be used for clinical applications. Here is the latest research on cell fate conversion by mRNA.